Check out our most popular compounded medications! Get Started
Papaverine HCl 150 mg Slow Release Capsules are formulated with Methocel E4M, a controlled-release polymer. This design allows for the gradual release of the active ingredient over an extended period, providing sustained therapeutic effects. This formulation is used to treat conditions such as Erectile Dysfunction, Raynaud's Syndrome, Intermittent Claudication, Priapism, and Peyronie's Disease. The slow release mechanism reduces dosing frequency and improves patient compliance, particularly for medications requiring a controlled and prolonged release profile.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Papaverine HCl 150 mg Slow Release Capsules is a prescription medication used to treat a variety of conditions, including erectile dysfunction, Raynaud's phenomenon, and spasms of the gastrointestinal tract. This formulation is uniquely designed with Methocel E4M, a type of controlled-release polymer, to gradually release the encapsulated medication or active ingredient, papaverine hydrochloride, over an extended period of time. This slow and sustained release mechanism offers sustained therapeutic effects, reduced dosing frequency, and improved patient compliance for medications requiring a controlled and prolonged release profile.
The recommended dosage of Papaverine HCl 150 mg Slow Release Capsules is one capsule taken orally once daily. To ensure a consistent therapeutic effect, it is advised that patients take the medication at the same time each day. It is important to note that this medication may take several weeks to reach its full therapeutic effect, hence patience and consistency in administration are key.
While Papaverine HCl 150 mg Slow Release Capsules is generally well tolerated, it may cause side effects such as nausea, headache, dizziness, and flushing. Patients experiencing any of these side effects should promptly contact their healthcare provider for advice and possible adjustment of the medication regimen.
If you have any questions about Papaverine HCl 150 mg Slow Release Capsules, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of experienced and dedicated pharmacists is always ready to provide the necessary guidance and support to ensure optimal therapeutic outcomes for our patients.
Papaverine HCl 150 mg Slow Release Capsules, formulated with Methocel E4M, a controlled-release polymer, are designed to gradually release the active ingredient over an extended period. This formulation offers sustained therapeutic effects, reduced dosing frequency, and improved patient compliance for medications requiring a controlled and prolonged release profile.
These capsules may interact with other medications, including those used to treat hypertension, angina, and erectile dysfunction. It is crucial for patients to inform their healthcare provider of all medications they are currently taking, including over-the-counter medications, vitamins, and herbal supplements. Additionally, any allergies or medical conditions that may affect the use of this medication should be disclosed to the healthcare provider.
Patients taking Papaverine HCl 150 mg Slow Release Capsules should avoid taking any other medications that contain papaverine or any other medications that may interact with this medication. Alcohol consumption should also be avoided while on this medication.
It is important to note that medications containing nitrates should not be taken concurrently with Papaverine HCl 150 mg Slow Release Capsules, as this may increase the risk of serious side effects. Other medications that may interact with this medication, such as anticoagulants, antiarrhythmics, or anticonvulsants, should also be avoided.
Furthermore, medications containing calcium channel blockers should not be taken in conjunction with Papaverine HCl 150 mg Slow Release Capsules, as this may increase the risk of serious side effects. Other medications that may interact with this medication, such as diuretics, beta-blockers, or ACE inhibitors, should also be avoided.
If you have any questions about the interactions of Papaverine HCl 150 mg Slow Release Capsules, please consult with your healthcare provider or pharmacist.
Papaverine HCl 150 mg Slow Release Capsules are a specialized formulation designed to treat a range of conditions such as erectile dysfunction, Raynaud's phenomenon, and spasms of the gastrointestinal tract. The capsules are formulated with Methocel E4M, a type of controlled-release polymer. This unique formulation allows for the gradual release of the active ingredient, Papaverine HCl, over an extended period of time. This slow release mechanism offers sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance, particularly for medications requiring a controlled and prolonged release profile.
Papaverine HCl works by relaxing the smooth muscles in the body, which can improve blood flow and reduce spasms. When taking Papaverine HCl 150 mg Slow Release Capsules, it is crucial to follow the prescribed dosage from your healthcare provider. The capsules should be taken with food and must not be crushed or chewed. Consistency is key, so taking the medication at the same time each day ensures a steady release of the medication.
While Papaverine HCl 150 mg Slow Release Capsules are generally well-tolerated, some patients may experience side effects such as nausea, dizziness, headache, and flushing. If you experience any of these side effects, it is important to contact your healthcare provider immediately. Always remember to discuss any concerns or questions you may have about Papaverine HCl 150 mg Slow Release Capsules with your healthcare provider or pharmacist.
Papaverine HCl 150 mg Slow Release Capsules, formulated with Methocel E4M, a controlled-release polymer, are designed to gradually release the encapsulated medication over an extended period of time. This formulation offers sustained therapeutic effects, reduced dosing frequency, and improved patient compliance for medications requiring a controlled and prolonged release profile. These capsules have been used off-label for a variety of conditions.
They have been utilized in the treatment of migraine headaches, spasticity, and bladder spasms. The capsules have also been used to alleviate symptoms of anxiety and depression. In patients with deep vein thrombosis, Papaverine HCl 150 mg Slow Release Capsules have been used to reduce the risk of blood clots. They have also been employed to decrease the risk of stroke in patients with atrial fibrillation.
For patients with coronary artery disease, these capsules may be used to reduce the risk of heart attack. They have also been used in the prevention of certain types of cancer, such as prostate cancer. In addition, Papaverine HCl 150 mg Slow Release Capsules may be used to reduce the risk of developing certain types of kidney stones.
Lastly, these capsules have been used to reduce the risk of developing certain types of eye diseases, such as glaucoma. If you have any questions about the use of Papaverine HCl 150 mg Slow Release Capsules for any of these conditions, please consult with a healthcare professional.
Papaverine HCl 150 mg Slow Release Capsules is a medication that is encapsulated in a controlled-release polymer, Methocel E4M. This formulation is designed to gradually release the active ingredient over an extended period of time.
Methocel E4M is a type of controlled-release polymer. It is used in the formulation to ensure that the medication is released gradually over a prolonged period, offering sustained therapeutic effects.
A slow-release formulation offers several benefits. It provides sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance, especially for medications that require a controlled and prolonged release profile.
The frequency of dosing will depend on your doctor's prescription. However, due to the slow-release formulation, the frequency of dosing is typically reduced compared to other formulations.
'Improved patient compliance' means that patients are more likely to take their medication as prescribed. This is because the slow-release formulation reduces the frequency of dosing, making it more convenient for patients.
No, the slow-release formulation does not affect the effectiveness of the medication. In fact, it enhances the therapeutic effects by ensuring a steady release of the medication over an extended period of time.
No, you should not break or crush the capsules. Doing so can interfere with the controlled-release mechanism and may lead to a sudden release of a large amount of the medication, which can be harmful.
If you miss a dose, take it as soon as you remember. However, if it is close to the time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double the dose to catch up.
Before starting any new medication, you should always inform your doctor about all the medications you are currently taking. This includes prescription medications, over-the-counter drugs, and any supplements.
If you experience any side effects, you should immediately report them to your doctor. Do not stop taking the medication without consulting your doctor.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
The conditions listed on this page are indications prescribers have ordered this preparation for. They are not FDA-approved indications, and listing them is not a statement that this preparation is effective for them.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice — discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
